A cure for amyotrophic lateral sclerosis remains out of reach, but the field has shifted in ways that would have been hard to imagine a decade ago. For most of its history, ALS research produced one approved drug that extended survival by roughly two to three months. In the past few years, the first therapy designed to attack a specific genetic cause of ALS reached the market, a handful of other gene-targeted approaches entered clinical trials, and regulators accepted a blood biomarker as evidence that a drug was working. None of this amounts to a cure, but the trajectory has changed from near-total therapeutic failure to cautious, measurable progress against specific forms of the disease.
Why ALS Is So Difficult to Treat
ALS kills motor neurons in the brain and spinal cord, progressively stripping away the ability to move, speak, swallow, and eventually breathe. Most people who are diagnosed live two to five years. The disease moves fast, which compresses the window for any treatment to work, and it attacks cells that the body cannot regenerate.
The deeper problem is that ALS is not one disease. In more than 95 percent of cases, a protein called TDP-43, which normally works inside the cell nucleus, ends up clumping in the wrong part of the cell. These clumps both poison the cell through their presence and starve it of a protein it needs, a double hit that leads to rapid motor neuron death.1PubMed Central. TDP-43-The key to understanding amyotrophic lateral sclerosis But TDP-43 misplacement is a feature shared across nearly all ALS cases, not its upstream cause. The causes are varied and, in many patients, still unknown.
Only about 5 to 10 percent of ALS cases are clearly inherited. Among those, a repeat expansion in a gene called C9ORF72 is the most common culprit, producing toxic protein fragments that accumulate in brain tissue early in the disease.2PubMed Central. The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD Mutations in the SOD1 gene, which encodes an enzyme involved in neutralizing free radicals, are another well-studied cause. These mutations make the protein misfold and aggregate, though the precise chain of events from misfolding to motor neuron death is still debated.3PubMed. Early steps in oxidation-induced SOD1 misfolding: implications for non-amyloid protein aggregation in familial ALS The remaining 90-plus percent of cases, called sporadic ALS, likely involve some combination of genetic susceptibility and environmental exposures, including heavy metals, pesticides, and other factors that remain poorly characterized.4PubMed Central. Amyotrophic lateral sclerosis and environmental factors
Adding another layer of complexity, the damage is not limited to motor neurons themselves. Surrounding glial cells, the support staff of the nervous system, become activated and contribute to neuron death through what researchers call a non-cell-autonomous pathway.5PubMed Central. Astrocytes and Microglia as Non-cell Autonomous Players in the Pathogenesis of ALS This means that even a treatment perfectly protecting motor neurons might fail if it ignores the inflammatory environment those neurons sit in. Any serious therapeutic strategy has to contend with multiple interacting mechanisms, genetic diversity among patients, and a disease that is often well advanced before it is diagnosed.
What Current Treatments Actually Accomplish
For over two decades, riluzole was the only approved drug for ALS. It works by dampening excessive glutamate signaling, which can overexcite and kill neurons. Across randomized trials and subsequent analyses, riluzole extends survival by about two to three months and improves the chance of living an additional year by roughly 9 percent.6PubMed Central. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis It is generally safe and well tolerated, but its benefit is modest by any standard.7PubMed. Riluzole for the treatment of amyotrophic lateral sclerosis
Edaravone, a free-radical scavenger approved in some countries, takes a different approach by reducing oxidative stress. In a Phase II study, patients treated with edaravone showed roughly half the decline on a standard functional scale compared to the six months before treatment, and markers of oxidative stress in spinal fluid dropped to nearly undetectable levels.8PubMed. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) However, the drug appeared to benefit mainly a subgroup of patients with early-stage disease and relatively fast progression, and its overall efficacy has been questioned.
A combination of sodium phenylbutyrate and taurursodiol was approved in 2022 based on trial data showing it slowed functional decline on the standard ALS rating scale compared to placebo over 24 weeks.9PubMed Central. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis The manufacturer later withdrew the drug from the market after a longer confirmatory trial failed to show a benefit, an outcome that underscored how fragile early positive signals in ALS can be.
The honest assessment of these older drugs is that they treat ALS the way aspirin treats a fever: they address downstream symptoms or byproducts of the disease without touching its root causes. The field needed a fundamentally different approach, and that is what has started to emerge.
Tofersen and the Arrival of Gene-Targeted Therapy
Tofersen, marketed as Qalsody, represents a genuine turning point. It is an antisense oligonucleotide, a short synthetic strand of genetic material designed to intercept and degrade the RNA produced by the mutant SOD1 gene. By reducing the amount of toxic SOD1 protein the body makes, tofersen attacks the upstream cause of one specific form of ALS rather than mopping up damage downstream.
The pivotal trial told a complicated story. Over 28 weeks, tofersen significantly reduced both SOD1 protein in spinal fluid and neurofilament light chain (a marker of nerve damage) in blood, but it did not hit its primary clinical endpoint of slowing functional decline.10PubMed. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS That sounds like a failure until you look at the longer-term data. In real-world clinical practice, patients on tofersen showed consistent drops in neurofilament light chain levels, with reductions averaging around 62 percent in blood and 66 percent in spinal fluid.11PubMed. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice Long-term follow-up out to nearly three years showed that early reductions in SOD1 and neurofilament light chain were sustained, with blood neurofilament levels dropping by about 67 percent from baseline and no sign of the drug losing its effect over time.12JAMA Neurology. Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis
The FDA approved tofersen through its accelerated pathway, accepting the reduction in neurofilament light chain as a surrogate marker for clinical benefit. This was a landmark regulatory decision. SOD1 mutations account for only about 2 percent of all ALS cases, so tofersen will never be a broadly applicable drug. But its importance extends far beyond the patients it directly helps. It proved that targeting a specific genetic cause of ALS can measurably slow the biological machinery of the disease, and it validated a biomarker-driven approach to drug approval that could accelerate the entire field.13PubMed Central. Entering the era of precision medicine to treat amyotrophic lateral sclerosis
Neurofilament Light Chain as a Game-Changing Biomarker
One of the biggest obstacles in ALS research has always been measurement. The standard tool for tracking disease progression, a questionnaire called the ALSFRS-R, captures how well patients perform daily tasks. It is useful but inherently noisy and slow to register change, which means clinical trials need large numbers of participants and long observation periods to detect a drug’s effect. For a rare disease where most patients live only a few years, that is a brutal bottleneck.
Neurofilament light chain, or NfL, is a structural protein released into the blood and spinal fluid when nerve fibers are damaged. Blood NfL levels in people with ALS are roughly four times higher than in healthy individuals, and the protein can distinguish ALS patients from controls with high sensitivity.14PubMed Central. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis Importantly, NfL levels in each individual stay relatively stable over time, making it possible to detect a drug-induced change against a person’s own baseline. The FDA’s decision to accept NfL reduction as the basis for tofersen’s approval marked a formal endorsement of the biomarker’s value.15PubMed Central. Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies
This matters practically because it could shrink the size and duration of future trials. If a drug can demonstrate a meaningful NfL reduction within months rather than requiring years of functional-scale data, promising therapies get to patients faster and failed ones get discarded sooner, freeing up resources. That said, NfL is a general marker of nerve damage, not specific to motor neurons or to ALS, and researchers are careful to note that it still needs more validation as a tool for predicting actual clinical improvement.16PubMed Central. Neurofilament light chain in drug development for amyotrophic lateral sclerosis
The Pipeline Beyond SOD1
Tofersen addresses 2 percent of ALS. The research community’s real ambition is to use the same antisense-oligonucleotide playbook against broader targets. One of the most watched approaches aims at TDP-43, the protein whose mislocalization marks nearly all ALS cases. Rather than targeting TDP-43 directly, which the cell still needs, researchers have focused on ataxin-2, a protein that helps TDP-43 form its toxic clumps. In mice engineered to develop TDP-43 pathology, a single injection of antisense oligonucleotides targeting ataxin-2 markedly extended survival.17PubMed Central. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice Other nucleic-acid therapies are being developed to target stathmin-2, a protein whose production is disrupted when TDP-43 leaves the nucleus.18PubMed. Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis If either of these strategies works in humans, the reach would be vastly wider than SOD1-targeted therapy.
Restoring TDP-43 to its normal balance within cells is another avenue under active investigation. Studies in cell and animal models suggest that correcting TDP-43 homeostasis can relieve neurodegenerative symptoms, providing proof-of-concept for the idea that the protein’s misbehavior is not just a bystander but a driver of disease.19PubMed. TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia
Gene therapy using viral vectors offers a complementary delivery system. Adeno-associated viruses, or AAVs, can carry therapeutic genes into neurons for long-term expression with minimal immune reaction. In mouse models of SOD1-linked ALS, AAV-delivered gene silencing has preserved motor function and extended survival, including when treatment was given after symptoms had already appeared.20PubMed Central. Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients – Section: AAV vectors The challenge has been getting these vectors across the blood-brain barrier efficiently and targeting the right cells without spreading to organs like the liver. Newer AAV capsid designs and spinal cord delivery routes have largely addressed those problems in animal studies, though human trials are still in early stages.21Current Gene Therapy. AAV as a Gene Transfer Vector for the Treatment of Neurological Disorders: Novel Treatment Thoughts for ALS
Immune-Based Strategies
The inflammatory side of ALS has attracted increasing attention. T cells, part of the adaptive immune system, appear to play a meaningful role in how fast the disease progresses. Research has found that T cell responses measured at the time of ALS diagnosis are associated with the pace of decline, suggesting that the immune system is not merely reacting to damage but actively contributing to it.22Nature Communications. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression
A specific type of T cell called a regulatory T cell, or Treg, normally acts as a brake on inflammation. In ALS, Treg numbers and function tend to decline as the disease worsens. The therapeutic logic is straightforward: boost Tregs, tamp down neuroinflammation, slow motor neuron loss. A phase 2 trial combining expanded Treg infusions with low-dose interleukin-2 (a growth factor for Tregs) found that the treatment was safe and well tolerated over a full year, and that it successfully increased both Treg numbers and their ability to suppress inflammation.23PubMed Central. Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis Whether that biological activity translates into meaningful clinical benefit is being tested in larger trials. Multiple Treg-centered strategies are now in development.24PubMed Central. From pathogenesis to therapy: the emerging role of regulatory T cells in amyotrophic lateral sclerosis
Stem cell approaches have also moved into clinical testing. Mesenchymal stem cells engineered to secrete neurotrophic factors, the chemical signals that keep motor neurons alive, showed biological activity in early-phase trials, improving cerebrospinal fluid biomarkers of neuroinflammation and neurodegeneration compared to placebo.25PubMed Central. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis The results are encouraging as proof of concept, but the path from biomarker improvement to slower disease progression is the same gap that has tripped up many ALS therapies before.
The Translation Problem
A recurring theme in ALS research is that promising results in mice do not carry over to people. Dozens of compounds that extended survival in the SOD1 mouse model, the field’s workhorse for decades, have failed in human trials.26PubMed. Lost in translation: treatment trials in the SOD1 mouse and in human ALS The reasons are instructive. The SOD1 mouse develops a very specific, aggressive form of motor neuron disease driven by a single mutation. Most human ALS is sporadic, genetically complex, and may involve different combinations of mechanisms in different patients. Treating the SOD1 mouse is more like targeting a single known poison than combating a syndrome with many contributors.
This recognition has pushed the field toward precision medicine, matching treatments to the specific genetic or molecular profile of each patient rather than trying to find one drug for everyone. The success of tofersen in SOD1-ALS is the first real-world validation of this approach. Advances in whole-genome sequencing are making it faster and cheaper to identify the genetic variants driving an individual patient’s disease, and large-scale “omics” studies are starting to define molecular subtypes of ALS that may respond to different therapies.13PubMed Central. Entering the era of precision medicine to treat amyotrophic lateral sclerosis The shift is from “one ALS, one cure” to “many subtypes of ALS, each needing its own intervention.” That is harder, but it is probably the only way forward for a disease this biologically diverse.
Digital Tools and Living With ALS
While researchers pursue disease-modifying therapies, technology is making practical differences for people living with ALS right now. Wearable devices that track movement at home are emerging as a more sensitive way to measure disease progression than periodic clinic visits. In one study, machine-learning models built from wearable sensor data detected functional decline faster than the standard clinical questionnaire and could have cut the number of participants needed for a clinical trial by roughly a third.27Nature Communications. At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis Accelerometry-derived metrics from the upper limbs have separately been shown to track progression over time and could serve as outcome measures in trials.28The Lancet Digital Health. Upper limb movements as digital biomarkers in people with ALS These digital biomarkers complement blood-based markers like NfL, making it possible to run faster, smaller, and cheaper trials.
Brain-computer interfaces are addressing one of the disease’s most devastating consequences: the loss of speech. Implantable systems that record neural signals from motor and sensory cortex can now decode the brain’s intended speech in real time, synthesizing it into audible, natural-sounding words. A recent report documented a voice-synthesis neuroprosthesis that restored fluent, naturalistic speech to a man with ALS.29PubMed Central. Brain–computer interface restores naturalistic speech to a man with ALS These systems are still experimental and surgically invasive, but they represent a qualitative leap from the eye-tracking and letter-board systems that most locked-in patients currently rely on.30Brain‐X. Advances in brain computer interface for amyotrophic lateral sclerosis communication
ALS and Frontotemporal Dementia as a Shared Spectrum
One area that is reshaping how researchers think about ALS is its overlap with frontotemporal dementia. Between 40 and 50 percent of people with ALS develop some degree of cognitive or behavioral symptoms associated with FTD, including problems with language, decision-making, and impulse control.31JAMA Neurology. Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum The C9ORF72 repeat expansion is the most common genetic cause of both diseases, and TDP-43 pathology appears in both. These two conditions are increasingly understood as opposite ends of a single spectrum rather than separate disorders.32PubMed Central. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia
This matters therapeutically because treatments developed for one condition may benefit the other. An antisense oligonucleotide targeting the C9ORF72 expansion, for instance, could in principle help both ALS and FTD patients who carry that mutation. It also matters diagnostically: if cognitive symptoms are part of the same disease process rather than a coincidental second condition, clinicians need to screen for them and factor them into care plans. The practical implication for patients and families is that ALS can involve more than muscle weakness, and understanding the cognitive dimension changes how the disease is managed day to day.
What “Close to a Cure” Actually Means Right Now
Honest researchers will tell you that a universal cure for ALS, a single treatment that stops or reverses the disease in everyone, is not on any realistic timeline. But the more nuanced picture is more hopeful than that statement alone suggests. For the small fraction of patients with SOD1 mutations, something resembling disease modification already exists. For C9ORF72 carriers, gene-targeted therapies are in clinical trials. For the broader population of sporadic ALS patients, the ataxin-2 and stathmin-2 strategies represent the first serious attempts to address TDP-43 pathology pharmacologically. Immune-based approaches and stem cell therapies are filling out the pipeline from different directions.
The field’s most significant structural change may be philosophical rather than pharmacological: the move away from searching for a single ALS drug toward building a toolkit of precision interventions, each targeted at a molecularly defined subset of patients. Combined with faster biomarker readouts, digital monitoring, and smaller-but-smarter trial designs, this approach could compress what used to take decades of incremental progress into something faster. Whether that is five years away or twenty depends on which subtype of ALS you are talking about and how the biology cooperates. The era of treating ALS as an untreatable disease is over; the era of treating it effectively for most patients has not yet arrived.